ArticleTranslational oncology2026

A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.

Zhe Geng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.